Mila is pleased to announce that bioMérieux, a global player in the field of in vitro diagnostics, is joining Mila's partner ecosystem. This partnership aims to develop innovative solutions to improve the accuracy and efficiency of in vitro diagnostic tools and detection of antibiotic resistance.
The partnership between bioMérieux and Mila will focus on the following areas:
- Research and development: Mila and bioMérieux aim, through a collaborative research project, to develop an AI model applied to genomic analysis. Among other applications, this project could improve the prediction of antibiotic resistance, and thus the value of genomic information for the diagnosis of infectious diseases.
- Scientific and technological surveillance: bioMérieux will benefit from access to Mila's scientific and technological resources, enabling bioMérieux's research teams to keep up with the latest advances in AI, and offering recruitment opportunities for young researchers.
Founded by Yoshua Bengio, winner of the 2018 Turing Award, and based in Montreal, Mila is an AI research institute distinguished by its expertise in deep learning, namely its community of over 1,300 researchers, as well as its commitment to advancing AI for social good, notably through an open science approach and groundbreaking initiatives in technology governance.
Céline Roger-Dalbert, Executive Vice-President of Research and Development at bioMérieux, comments: “We are joining forces with a partner with an international reputation in applied research and a vast pool of talent. For us, it's a vector for development, enabling us to go even further in diagnostic innovation”.
“The fight against antimicrobial resistance is a major public health challenge, and AI represents a unique opportunity to accelerate the development of diagnostic tools. Mila is pleased to welcome bioMérieux, a world leader in in vitro diagnostics, to its community of partners,” said Stéphane Létourneau, Executive Vice-President of Mila.
For over 60 years, bioMérieux has stood out for its innovation and commitment to pushing the boundaries of diagnostics to improve public health. The company invests 12% of its sales each year in R&D to design cutting-edge diagnostic solutions. This partnership with Mila is a further illustration of the quest for innovation that lies at the heart of bioMérieux’s public health mission.
About bioMérieux
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products. www.biomerieux.com.
